News

See our latest news

News

Kashiv's Lab Imagery

December 10, 2024

Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer

November 1, 2024

Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO

July 25, 2024

Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)

July 1, 2024

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

October 3, 2023

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

October 2, 2023

Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to Xolair® (omalizumab)

July 5, 2023

Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)

May 31, 2022

Kashiv BioSciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)

March 2, 2022

Kashiv BioSciences Receives Approval for Its First Biosimilar Releuko™ (filgrastim-ayow)